慢性HBV携带者肝组织Fas和Fas配体表达变化及其意义

doi:10.3969/j.issn.1672-5069.2014.01.015

摘要/Abstract

摘要： 目的观察慢性HBV携带者（chronic asymptomatic HBV carrier,ASC）肝组织Fas和Fas配体（FasL）的表达和血清可溶性Fas（sFas）水平的变化。方法对120例ASC行肝穿刺,采用免疫组织化学法检测肝组织Fas和FasL表达,采用ELISA法检测血清sFas水平。结果120例ASC肝组织完全正常者仅占11%,轻度肝炎占59%,而中、重度肝炎占30%;表现正常的肝组织无Fas和FasL表达,轻度肝炎肝组织多无表达或仅限于界面炎症区的肝细胞及淋巴细胞阳性表达,而中、重度肝炎肝组织Fas和FasL多为阳性,Fas强阳性率分别达34.8%和69.2%,FasL强阳性率分别达30.4%和53.8%,均明显高于正常组和轻度炎症组（P<0.05）,同时中、重度肝炎组间也存在显著性差异（P<0.05）,其分布除界面炎症区外,肝小叶中也弥漫分布;肝组织表现正常的ASC血清sFas水平为（1.68±0.33）ng/L,而轻、中、重度肝炎患者则分别为（2.58±0.31）ng/L、（3.94±0.21）ng/L和（5.94±0.26）ng/L,均较正常组显著升高（F=218.01,P<0.01）,各组间sFas水平也均具有统计学差异（P<0.01）。结论Fas和FasL介导的肝细胞凋亡在慢性HBV携带者肝组织病变中可能起到了重要作用。

关键词: 慢性HBV携带者, 凋亡, Fas, Fas配体

Abstract: Objective To investigate the expression of Fas antigen and Fas ligand（FasL） in liver tissues from chronic asymptomatic hepatitis B virus （HBV） carrier （ASC）. Methods Liver biopsy specimen and sera from 120 individuals with ASC were obtained;The expression of Fas and FasL in liver tissues were detected by immunohistostaining. Serum levels of soluble Fas （sFas） and sFasL were measured by ELISA. Results Only 11% had a normal appearance of liver tissues in the 120 chronic HBV carriers,and 59% had mild and other 30% had moderate to severe hepatitis;Fas and FasL were negative in normal liver tissues,almost absent or only slightly positive in hepatocytes and lymphocytes in inflammatory zone of the interface in liver tissues with mild hepatitis,and strongly positive in those with moderate or severe hepatitis,showing a pattern of diffused staining in the interface area of hepatic lobules;The strongly positive rate for Fas and FasL in moderate（34.8% and 30.4%,respectively） and severe hepatitis（69.2% and 53.8%,respectively） was significantly higher than that in mild hepatitis or normal liver tissues（P<0.05）;Serum sFas from persons with normal liver tissues was（1.68±0.33） ng/L,and they increased significantly to（2.58±0.31） ng/L,（3.94±0.21） ng/L and（5.94±0.26） ng/L,respectively,from individuals with mild,moderate and severe hepatitis（P<0.01）. Conclusion The Fas-FasL mediated apoptosis might play an important role in the disease progress of ASC.

Key words: Chronic asymptomatic hepatitis B virus carrier, Apoptosis, Fas, Fas ligand

代雪枫, 马勇, 徐长江, 王莉. 慢性HBV携带者肝组织Fas和Fas配体表达变化及其意义[J]. 实用肝脏病杂志, 2014, 17(1): 51-54.

Dai Xuefeng, Ma Yong, Xu Changjiang. Expression of Fas and Fas ligand in liver tissues from chronic asymptomatic hepatitis B virus carriers[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 51-54.

参考文献

[1] 张立洁,王欣欣,孟忻. 慢性HBsAg携带者及非活动性HBV感染状态的病理学研究. 临床肝胆病杂志,2007,23（5）：337-339.
[2] 刘耕陶,斯崇文,王勤环. 对我国慢性病毒性肝炎防治与研究工作的建议. 中华医学杂志,2002,82（2）：13-18.
[3] Liaw YF. Natural history of chronic hepatitis B infection and long-term outcome under treatment. Liver Int,2009,29（suppl1）：100-107.
[4] 中华医学会传染病与寄生虫病学分会和肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8（6）：324-329.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[6] 叶立红,梅志勤,刘彦超,等. 162例慢性HBV携带者HBV DNA载量与肝组织炎症坏死程度的相关性. 临床肝胆病杂志,2007,23（5）：27-32.
[7] 张小东. 浅谈乙肝表面抗原携带者的诊疗及预后.现代中西医结合杂志,2008,15（3）：411-412.
[8] Zhang M,He W,Liu F,et al. Inhibition of mouse hepatocyte apoptosis via anti-Fas ribozyme. World J Gastroenterol,2004, 10（17）：412-418.
[9] Choudhury JA,Ruessel CL,Randhaws S,et al.Differential induction of nuclear Factor-KB and activator protein-1 activity after CD40 ligation is associated with primary human hepatocyte apoptosis or intrahepatic endothelial cell proliferation. Mol Boil Cell,2003,44：1334-1341.
[10] Ockner RK. Apoptosis and liver disease：recent concepts of mechanism and significance. J Gastroenterol Hepatol,2001,16：248-260.
[11] 马清峰,王威. 慢性乙型肝炎患者IL-18、Fas检测的临床意义.实用医学杂志,2010,26（7）：1181-1182.
[12] 宋修光,马立宪. 乙型肝炎患者肝细胞Fas和血清可溶性s Fas与肝脏损伤的关系. 临床检验杂志,2007,25（1）：32-33.
[13] 盛云建,宋新文. 慢性乙型肝炎患者外周血淋巴细胞Fas表达和凋亡的检测及意义. 中国煤炭工业医学杂志,2008,11（3）：317-318.
[14] 邢文斌,刘丽娜,吕申. Fas、FasL在慢性乙型肝炎患者肝细胞和外周血淋巴细胞上的表达. 临床肝胆病杂志,2007,23（1）：11-13.
[15] Jun EJ,Han JY,Sun HS. Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B. Korean J Hepatol,2006,12（4）:507-514.
[16] Lapinski TW. The concentration of Fas in the serum and liver tissue in viral chronic hepatitis B patients treated with lamivudine. Hepatogastroenterology,2005,52（62）:575-579.
[17] Oksuz M,Akkiz H,Isiksal YF,et al. Expression of Fas antigen in liver tissue of patients with chronic hepatitis B and C. Eur J Gastroenterol Hepatol,2004,16（3）:341-345.
[18] Song le H,Binh VQ,Duy DN,et al. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus. J Med Virol,2004,73（2）:244-249.
[19] Lee JY, Chae DW,Kim SM,et al. Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection. J Viral Hepat,2004,11（2）:130-135.
[20] Jung YJ,Kim YJ,Kim LH,et al. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection. Intervirology,2007,50（5）:369-376.